default author photo

Wieneke A. Buikhuisen

Netherlands Cancer Institute - Department of Thoracic Oncology

Postbus 90203

Amsterdam, 1006 BE

Netherlands

SCHOLARLY PAPERS

1

DOWNLOADS

80

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Switch Maintenance Gemcitabine after First Line Chemotherapy in Patients with Malignant Mesothelioma: A Randomized Open Label Phase II Trial (NVALT19)

Number of pages: 53 Posted: 31 Jan 2020
Cornedine J. de Gooijer, Vincent van der Noort, Jos A. Stigt, Paul Baas, Bonne Biesma, Robin Cornelissen, Nico van Walree, Robbert C. van Heemst, Magdolen Youssef-El Soud, Harry J.M. Groen, Agnes J. Staal-van den Brekel, Wieneke A. Buikhuisen, Gerben P. Bootsma, Floris Dammeijer, Harm van Tinteren, Ferry Lalezari, Joachim G. J. V. Aerts, Jacobus A. Burgers and NVALT19 Study Team
Netherlands Cancer Institute - Department of Thoracic Oncology, Netherlands Cancer Institute, Isala Hospital, Netherlands Cancer Institute - Department of Thoracic Oncology, Jeroen Bosch Hospital, Erasmus University Rotterdam (EUR) - Cancer Institute, Amphia Hospital, Deventer Hospital, Maxima Medical Centre, University of Groningen - Department of Pulmonary Diseases, Ziekenhuis Groep Twente, Netherlands Cancer Institute - Department of Thoracic Oncology, Zuyderland Medical Centre, University Medical Center Rotterdam - Erasmus MC Cancer Institute, Netherlands Cancer Institute - Department of Biometrics, Netherlands Cancer Institute, Erasmus University Rotterdam (EUR) - Cancer Institute, Netherlands Cancer Institute - Department of Thoracic Oncology and affiliation not provided to SSRN
Downloads 80 (803,225)

Abstract:

Loading...

Mesothelioma; gemcitabine; maintenance; randomised; NVALT; phase II